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Abstract
Background: Over two thirds of women who need contraception in Uganda lack access to modern effective methods. This
study was conducted to estimate the potential cost-effectiveness of achieving universal access to modern contraceptives in
Uganda by implementing a hypothetical new contraceptive program (NCP) from both societal and governmental (Ministry
of Health (MoH)) perspectives.
Methodology/Principal Findings: A Markov model was developed to compare the NCP to the status quo or current
contraceptive program (CCP). The model followed a hypothetical cohort of 15-year old girls over a lifetime horizon. Data
were obtained from the Uganda National Demographic and Health Survey and from published and unpublished sources.
Costs, life expectancy, disability-adjusted life expectancy, pregnancies, fertility and incremental cost-effectiveness measured
as cost per life-year (LY) gained, cost per disability-adjusted life-year (DALY) averted, cost per pregnancy averted and cost
per unit of fertility reduction were calculated. Univariate and probabilistic sensitivity analyses were performed to examine
the robustness of results. Mean discounted life expectancy and disability-adjusted life expectancy (DALE) were higher under
the NCP vs. CCP (28.74 vs. 28.65 years and 27.38 vs. 27.01 respectively). Mean pregnancies and live births per woman were
lower under the NCP (9.51 vs. 7.90 and 6.92 vs. 5.79 respectively). Mean lifetime societal costs per woman were lower for the
NCP from the societal perspective ($1,949 vs. $1,987) and the MoH perspective ($636 vs. $685). In the incremental analysis,
the NCP dominated the CCP, i.e. it was both less costly and more effective. The results were robust to univariate and
probabilistic sensitivity analysis.
Conclusion/Significance: Universal access to modern contraceptives in Uganda appears to be highly cost-effective.
Increasing contraceptive coverage should be considered among Uganda’s public health priorities.
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Introduction
With a fertility rate of 6.7 and an annual population growth rate
of 3.2%, Uganda has one of the fastest growing populations in the
world [1]. This is due in part to low contraceptive use. Among
fecund married or unmarried, sexually active women who desire
contraception, only 31% use modern contraceptive methods; 61%
lack access, and 8% use traditional methods [2]. Other African
countries have similar contraceptive access problems. In Ethiopia
for instance, only 29% of fecund married or unmarried, sexually
active women who desire contraception use modern methods [3].
This results in many unintended pregnancies and unplanned
births. In Uganda, 45% of births in 2006 were unplanned and
women have more children per woman (6.7) than they want (5.1)
[1]. More unintended pregnancies occur among non-contracep-
tive users (88%) than due to contraceptive failure (12%) [2].
Contraception is beneficial to individuals, families and society,
and contributes to improved health and socioeconomic develop-
ment [4–6]. But despite these potential benefits, access to
contraceptives in Uganda is declining, and the government has
not responded appropriately [7]. With a per capita health
expenditure of US$44 (at the average exchange rate) or
International$112 (purchasing power parity) [8], Uganda’s
government-run healthcare system must prioritize among the
many competing health needs of the population because of the
extreme budget constraint. Consequently, many beneficial health-
care interventions may not be implemented.
Cost-effectiveness analysis considers both costs and health
outcomes in evaluating the efficiency of interventions and allows
policy makers to prioritize among competing uses of healthcare
resources. The objective of this study was to compare the
incremental cost-effectiveness of a hypothetical new contraceptive
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contraceptives in Uganda, to the current contraceptive program
(CCP), i.e., the status quo in which access to modern contraception
is limited. In this study, we assumed that the NCP would have an
identical proportional distribution of modern contraceptive
methods as is currently used in Uganda but with the unmet need
for contraception removed i.e. all fecund married or unmarried,
sexually active women who desire contraception, an estimated
total of 3,200,000 women, use modern methods and none use
traditional methods [1]. Table 1 shows the number and percent
distribution of these women’s use of different kinds of contracep-
tion under the CCP and the hypothetical NCP.
Methods
Markov Model
A Markov cohort model was developed to assess the potential
cost-effectiveness of the NCP compared to the CCP. The model
projected the reproductive health experience of a hypothetical
cohort of 15-year old girls over a lifetime horizon. The starting age
of the hypothetical cohort was chosen to reflect as closely as
possible the median age of sexual debut in Uganda – 16.6 years
[1]. Figure 1 shows a schematic of the Markov model.
The Markov model is suited to women’s reproductive
experience because it spans many years and many events –
pregnancies, miscarriages, abortions and births – that can occur
multiple times. For instance, women face multiple opportunities to
get pregnant with the probability of pregnancy diminishing with
each subsequent cycle as the individual ages. The model had 7
states: (i) not sexually active (NSA); (ii) intentional non-contracep-
tion (INC); (iii) unintentional non-contraception (UNC); (iv)
modern contraception (MOC); (v) traditional contraception
(TRC); (vi) pregnant and (vii) dead. The INC state included
women who were looking to get pregnant and the UNC state
included women who lacked access to modern contraception. The
cycle time was 9 months. The model assumed a constant modern
contraceptive use mix across all ages for women on contraception.
The model was checked (de-bugged) by varying transition
probabilities between 0 and 1 to observe if responses were logical
and setting costs and outcomes to 0 separately to examine if the
expected values were identical. Validation was performed by
comparing the predicted fertility to the published estimate for
Uganda [1].
The analysis was performed from both the governmental
(Ministry of Health (MoH)) and the societal perspectives and
included direct and indirect costs. The MoH perspective included
direct medical costs and direct non-medical costs that are incurred
by the MoH which is the healthcare provider in Uganda and the
societal perspective included, in addition to these, the direct non-
medical costs incurred by patients (such as transportation) and
indirect (productivity) costs. Costs and outcomes were discounted at
3%peryear[9].TheNCPwascomparedtotheCCPonthebasisof
costs, life expectancy and incremental cost-effectiveness analysis
using cost per life-year (LY) saved and disability-adjusted life years
(DALY) averted to capture both quality and quantity of life. The
model was also used to compute other intermediate measures of
cost-effectiveness: 1) cost per pregnancy averted; 2) cost per unit of
fertility reduction; 3) cost per ectopic pregnancy averted; 4) cost per
miscarriageaverted;5)costperinducedabortionaverted;6)costper
still birth averted 7) cost per neonatal death averted; 8) cost per
infant death averted; and 9) cost per child death averted.
A threshold for cost-effectiveness with ranges from 1 to 3 times
per capita GDP per DALY averted has been suggested [10–12] and
other studies have used this threshold in Uganda [13,14]. Uganda’s
GDP per capita was $474 in 2010 [15]. Therefore the NCP was
judged to be highly cost-effective if the incremental cost-effective-
ness ratio (ICER) was less than $474 per DALY and cost-effective if
the ICER was less than $1423 per DALY (3 times per capita GDP).
Starting distribution of the hypothetical cohort among
Markov states
The proportion of 15-year olds who reported no sexual activity
in the 3 months prior to the 2006 UDHS (80.3%) was started in
the NSA state [1]. In the CCP, the remaining 19.7% who were
sexually-active women were divided among the other states: 9.1%
who used modern contraception started in the MOC state; 1.8%
who used traditional contraception started in the TRC state; 6.6%
who lacked access started in the UNC state; and the remaining
2.1%, considered to want to conceive, started in the INC state [1].
In the NCP, 17.6% (who started in the MOC, TRC, and the
UNC states) were started in the MOC state, akin to universal
access to modern contraception, and 0% was started in the INC
and TRC states.
Transition probabilities
Transition probabilities between states of contraceptive use over
a woman’s life were computed using UDHS data and were age-
specific within five-year age intervals (Table 2) [1]. The proportion
of women who remained sexually inactive represented the
probability (by age group) of staying in the NSA state (UDHS
2006; Table 7.7.1 (Page 93)) [1]. Sexual activity was defined as
reported sexual activity within the previous 4 weeks, consistent
with the UDHS definition [1]. The proportion of women using
traditional and modern contraception (UDHS 2006; Table 6.2.1
(Page 67)) [1] represented the probability (by age group) of
transition between both the NSA and UNC states and MOC and
TRC states respectively. The proportion of sexually active women
Table 1. Number and percentage of fecund married or
unmarried, sexually active women in Uganda who desire
contraception and the different kinds of contraceptive
methods under the CCP and NCP*.
CCP NCP
n% n%
All women 3,200,000 100.0 3,200,000 100.0
No contraception 1,952,000 61.0 0 0
Any method 1,248,000 39.0 3,200,000 100.0
Any modern 992,000 31.0 3,200,000 100.0
Female sterilization 108,800 3.4 352,000 11.0
Male sterilization 6,400 0.2 19,200 0.6
Pill 147,200 4.6 473,600 14.8
Intrauterine device (IUD) 6,400 0.2 19,200 0.6
Injectable 496,000 15.5 1,600,000 50.0
Implants 19,200 0.6 60,800 1.9
Male condom 204,800 6.4 659,200 20.6
Any traditional 256,000 8.0 0 0
Rhythm 124,800 3.9 0 0
Withdrawal 86,400 2.7 0 0
Folk method 44,800 1.4 0 0
CCP – Current Contraceptive Program; NCP – New Contraceptive Program.
*Assumes identical distribution of modern methods as is currently used.
doi:10.1371/journal.pone.0030735.t001
Cost-Effectiveness of a Contraception Program
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30735lacking access to modern contraception (UDHS 2006; Table 7.7.1
(Page 93) [1] represented the probability (by age group) of
transition between the NSA and UNC states. The proportion of
sexually active women who wish to conceive was calculated by
subtracting the sum of the proportions (by age group) of women
who use contraceptives and women who lack access to
contraceptives from 1. The resulting proportion represented the
probability of transition from the NSA state to the INC state.
The probability of pregnancy without contraception (85%) [16]
represented the probability of transition from the UNC and INC
states to the pregnant state. This probability was adjusted for the
age-specific prevalence of menopause (defined as last known
menstrual period occurring 6 or more months prior to survey
among non-pregnant and non-amenorhoeic women (UDHS 2006;
Table 7.10 (Page 98)) [1], which increases from 2.4% between 30
and 34 years to 42.8% between 48 and 49 years of age. The rate of
contraceptive failure on traditional contraception (20%) and
modern contraception (3%) [16] represented the probability of
transition between the TRC and MOC states and pregnancy. The
failure rate for modern contraceptive use was weighted by the
frequency of use of different modern methods in Uganda [1].
The probability of intentional and unintentional contraceptive
discontinuation, estimated in an Eastern African study at 16.7%
and 12.1% respectively [17], represented the probability of
transition between the MOC state and INC and the MOC and
TRC states respectively, assuming that women who lose access to
modern contraception opt for traditional contraception.
Women who had live births transitioned to the MOC state
because the probability of pregnancy during lactation amenorrhea
is similar to the probability of pregnancy on modern contraceptives
[18]. Women who had non-live birth pregnancy outcomes
transitioned to other states at the same rate as women in the NSA
state. Transitions between the MOC and TRC states in a single
cycle as well as movement from contraceptive use states to the NSA
Figure 1. Markov model. The model illustrates the different states of contraception through which women between 15 and 49 years of age in
Uganda transition. Each state is associated with a cost and a value of disability-adjusted life years lost. All states may progress to dead.
doi:10.1371/journal.pone.0030735.g001
Table 2. Age-specific transition probabilities from different
states of contraceptive use, pregnancy and death.
Age group 15–19 20–24 25–29 30–34 35–39 40–44 45–49
NSARINU 0.02 0.17 0.17 0.12 0.08 0.05 0.13
NSARUNU 0.07 0.21 0.26 0.29 0.29 0.27 0.19
NSA/UNURMOD 0.09 0.17 0.19 0.22 0.19 0.21 0.19
NSA/UNURTRA 0.02 0.03 0.04 0.04 0.04 0.06 0.05
NSARNSA 0.80 0.41 0.34 0.31 0.39 0.41 0.47
UNU/INURPRE* 0.85 0.85 0.85 0.83 0.81 0.69 0.17
UNURto UNU 0.07 0.05 0.05 0.05 0.06 0.16 0.53
All statesRDead
y 0.002 0.003 0.006 0.009 0.012 0.011 0.011
NSA – Not Sexually Active; INU – Intentional Non-Use of contraception; UNU –
Unintentional Non-Use of contraception; MOD – Modern contraception; TRA –
Traditional Contraception; PRE – Pregnant.
*Initial estimate of 85% probability of pregnancy is adjusted for proportion of
women who are menopausal by age.
yGender and age-specific mortality rate for Uganda converted to a nine-month
transitional probability.
doi:10.1371/journal.pone.0030735.t002
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state only after pregnancy. Pregnancy was a temporary state i.e.
women did not spend more than a single cycle in this state.
All estimates reported as annual probabilities were converted
into 9-month transition probabilities to reflect the cycle time of the
model. The changing probability of different events such as
pregnancy over time as women age (time-dependency) was
captured in the model by using age-group-specific tables in lieu
of the relevant transition probabilities. This enabled members of
the simulated cohort of different ages to be assigned their relevant
age-specific transition probabilities.
The non-age-specific transition probabilities are shown table 3.
Mortality
Age-specific mortality rates from all causes for women in
Uganda were obtained from country-specific life tables published
by the World Health Organization [19] and are shown in table 2.
These were adjusted for the percentage of deaths due to maternal
causes which is 13% [1]. Maternal mortality is 435 (345–524)
deaths per 100,000 live births [1]. This estimate was adjusted for
the proportion of pregnancies that result in live births. Neonatal,
infant and child mortality estimates (table 3) were obtained from
the UDHS [1] and are represented cumulatively i.e. infant
mortality includes neonatal mortality and child mortality includes
both neonatal and infant mortality.
Disability-Adjusted Life Years (DALYS)
Annually, there are an estimated 498,000 DALYs lost due to
maternal causes (pregnancy complications) in Uganda [20] and an
estimated 1,830,000 pregnancies [21]. Therefore the average
DALY loss due to pregnancy complications associated with a
single pregnancy is 0.27.
Costs
Costs were estimated for the pregnant (PRE) and modern
contraception (MOC) Markov states only; we assumed that the
Table 3. Parameters of the Markov model.
Parameter Base case Sensitivity range* Reference
Transition probabilities
MODRPRE 0.03 0.02–0.03 [16]
TRARPRE 0.20 0.16–0.24 [16]
MODRINU 0.25 0.20–0.29 [17]
MODRUNU 0.34 0.27–0.41 [17]
TRARINU 0.26 0.21–0.31 [17]
TRARUNU 0.36 0.27–0.41 [17]
PRERNSA
Q 0.73 0.58–0.88 [1,21,26–28]
PRERINU 0.03 0.02–0.04 [1,21,26–28]
PRERUNU 0.06 0.05–0.08 [1,21,26–28]
PRERMOD 0.04 0.03–0.05 [1,21,26–28]
PRERTRA 0.01 0.01–0.02 [1,21,26–28]
PRERDead
y 0.0034 0.0028–0.0041 [1]
Pregnancy Complications
Miscarriage 0.049 0.039–0.059 [27]
Ectopic pregnancy 0.014 0.011–0.017 [26]
Abortion 0.190 0.152–0.059 [21]
Still birth 0.017 0.014–0.020 [28]
Mortality
Neonatal mortality 0.021 0.017–0.025 [1]
Infant mortality 0.055 0.044–0.067 [1]
Child mortality 0.049 0.030–0.120 [1]
Life expectancy (2.5 years) 51.7 – [19]
DALYs lost
Maternal conditions 0.272 0.218–0.327 [20]
Costs ($US)
Contraception (MOH) 14.67 7.34–22.01 [22,23]
Contraception (Societal) 64.74 32.39–97.16 [22,23] Primary study
Pregnancy (MOH) 96.65 48.32–144.97 [22,23]
Pregnancy (Societal) 254.33 127.13–381.49 [15,22,23] Primary study
*Sensitivity ranges are based on 95% confidence intervals where available or represent +/250% for costs and +/220% for other parameters.
QAlso probability of live birth. Calculated by subtracting ectopic pregancies, induced abortions, miscarriages and still births.
yMaternal mortality.
doi:10.1371/journal.pone.0030735.t003
Cost-Effectiveness of a Contraception Program
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30735other Markov states – NSA, INC, UNC, TRC and DEAD – bore
no costs. For these two states, we estimated direct medical costs,
direct non-medical costs, and indirect costs.
In the MOC state, the direct medical costs included the cost of
contraceptive technology, weighted by the prevalence of the use of
the different methods [22], the cost of healthcare personnel [23],
transportation costs [24], costs of upkeep [24], and out-of-pocket
costs when patients seek contraceptive services [23]. The direct
non-medical costs included overhead costs and capital costs for
out-patient care in Uganda obtained from the WHO WHO-
CHOICE database [25]. The indirect costs included the costs of
lost time when women seek health services [24]. The costs of
different contraceptive different contraceptive technologies and
their prevalence of use are shown in table S1 and the costs of other
inputs are shown in table S2.
In the PRE state, the different cost categories were estimated for
antenatal care and the different potential outcomes of pregnancy –
miscarriage, induced abortion, ectopic pregnancy, birth (still and
live; vaginal and cesarean), obstetric hemorrhage, and eclampsia,
weighted by their incidence [1,21,23,26–28]. The direct medical
costs included the costs of healthcare personnel [23] and other
healthcare materials [23], transportation costs [24], costs of upkeep
[24], and out-of-pocket costs when patients seek different services
[23,24]. The direct non-medical costs included the overhead and
capital costs associated with different services [25] and the indirect
costs included the productivity costs associated with lost time while
seeking care for different services [24]. The costs of different inputs
by pregnancy outcome are shown in table S3 and the incidence of
pregnancy outcomes, unit costs and total costs of pregnancy from
the MoH and societal perspective are shown in table S4. A detailed
description of the estimation of the costs of modern contraception
and pregnancy is given in Appendix S1.
All costs were in 2010 US dollars.
Sensitivity Analysis
Sensitivity analyses were performed to determine which variables
had substantial impact on costs and outcomes. All parameters were
assigned a range of plausible values using 95% confidence intervals
when available or +/250% for costs and +/220% for other
parameters (table 2). To further test the robustness of our results, we
conducted a probabilisticsensitivityanalysis. We created probability
distributions for all of the parameters in the model except those
relating to the underlying methods of the analysis such as the
discount rate [29]. For all other parameters, the base-case value was
used for the mean, and the standard error was estimated based on
the approximation that the range used for one-way sensitivity
analyses represented a 95% confidence interval, with the range
approximately equal to four times the standard error [29]. A Beta
distribution was used for probabilities and DALYs because it is
boundedontheinterval0–1and resemblesanormaldistributionfor
someparameterisations and a normal distribution was used for costs
because we were not overly concerned with skewness as to use a log-
normal or gamma distribution [29]. Monte Carlo simulation was
used to create 10,000 iterations for which the expected outcome
values were calculated. The probability that either intervention was
cost-effective was then calculated for a range of cost-effectiveness
thresholds.
Data analysis was performed using TreeAge Pro.
Results
Model testing and validation
The model was tested (de-bugged) by varying transition
probabilities between 0 and 1 (which resulted in logical responses)
and setting costs and outcomes to 0 separately (which resulted in
identical expected values). With regard to validation, we used the
predicted fertility as the main benchmark and the model predicted
the total fertility rate in Uganda fairly well (6.92 vs. 6.70) [1].
Cost-consequences analysis
For a hypothetical cohort of 100,000 15-year old women, the
NCP would result in savings of $3.78 million in societal costs, or
$4.88 million in MoH costs. The NCP would also result in,
160,000 fewer pregnancies and 113,000 fewer births. Table 4
shows detailed results of the cost-consequences analysis including
the impact on other outcomes such as abortions and ectopic
pregnancies.
Base case analysis
Table 5 is a summary of the baseline results of the cost-
effectiveness analysis. Mean discounted life expectancy was higher
under the NCP (28.74 vs. 28.65 years). The mean discounted
disability-adjusted life expectancy was also higher under the NCP
(27.38 vs. 27.01). The mean number of pregnancies per woman
would be reduced from 9.51 under the CCP to 7.90 under the
NCP, reducing the total fertility rate from 6.92 to 5.79. Other
maternal and child health outcomes were also more favorable
under the NCP: 0.02 fewer ectopic pregnancies, 0.07 fewer
miscarriages, 0.29 fewer abortions, 0.02 fewer still births, 0.03
fewer neonatal deaths, 0.09 fewer infant deaths, and 0.16 fewer
child deaths per woman on average.
Mean lifetime societal costs per woman were lower for the NCP
from the societal perspective ($1,949 vs. $1,987) and the MoH
perspective ($636 vs. $685). The NCP increased program costs
from both the societal perspective (by $225) and the MoH
perspective (by $51) but reduced medical costs from both the
societal perspective (by $267) and the MoH perspective (by $101).
Therefore the net lifetime costs (program costs minus averted
medical costs) were $422 from the societal perspective and $55
from the MoH perspective.
Table 4. Results of a cost-consequences analysis for a
hypothetical cohort of 100,000 Ugandan women.
CCP NCP Difference
Societal costs ($US) $198,729,000 $194,940,000 2$3,789,000
MOH costs ($US) $68,481,000 $63,603,000 2$4,878,000
Pregnancies 950,000 790,000 2160,000
Discounted Life years 2,865,000 2,874,000 9,000
Discounted DALE (years) 2,701,000 2,738,000 37,000
Ectopic pregnancies 13,300 11,100 22,200
Induced abortions 180,000 151,000 229,000
Miscarriages 46,000 39,000 27,000
Still births 16,000 14,000 22,000
Live births 692,000 579,000 2113,000
Neonatal deaths 20,000 17,000 23,000
Infant deaths 53,000 44,000 29,000
Child deaths 95,000 79,000 216,000
CCP – Current Contraceptive Program; NCP – New Contraceptive Program; MoH
– Ministry of Health; DALE – Disability-Adjusted Life Expectancy.
doi:10.1371/journal.pone.0030735.t004
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both the societal perspective and the MOH perspective i.e.
resulted in reduced costs and more favorable outcomes.
We calculated ICERs for different outcomes (denominators)
and with the costs (numerator) remaining the same. As in the
baseline analysis, and from both the societal perspective and the
MoH perspective, the NCP dominated the CCP i.e. resulted in
reduced costs and more favorable outcomes. Table 6 summarizes
the reduction in costs and improvement in a variety of outcomes
comparing the NCP to the CCP.
Sensitivity analysis
Univariate sensitivity analyses (Figure 2) showed that the
incremental societal cost was most sensitive to the uncertainty
surrounding the costs of contraception and pregnancy. Incremen-
tal disability-adjusted life expectancy was most sensitive to the
uncertainty surrounding the discount rate and the probability of
modern contraception discontinuation. Probabilistic sensitivity
analysis (Figure 3) showed that all cost-effectiveness pairs obtained
from probabilistic sensitivity analysis lie in the ‘‘southeast’’ and
‘‘northeast’’ quadrants indicating a great deal of certainty that the
NCP is more effective than the CCP and that there is some
uncertainty as to whether the NCP is less costly than the CCP.
Figure 4 is a cost-effectiveness acceptability curve which shows the
probability that the NCP is cost-effective compared to the CCP for
the range of values of willingness to pay constrained at three times
Uganda’s GDP per capita, a commonly used standard. It shows
that the proportion of iterations in which the NCP is more cost-
effective compared to the CCP approaches 100% at a cost-
effectiveness threshold of much less than $474, Uganda’s GDP per
capita.
Discussion
Using a Markov model, this study found that a hypothetical new
contraceptive program (NCP) to achieve universal access to
modern contraceptives in Uganda would be highly cost-effective,
dominating the current contraceptive program (CCP) in the
incremental analysis by achieving improved outcomes at a reduced
cost. And findings were robust to univariate and probabilistic
sensitivity analyses.
In addition to limiting the adverse health consequences of
unintended pregnancies, contraception contributes towards
achieving two of the eight Millennium Development Goals
(MDGs) by reducing the number of unplanned births, reducing
child morbidity and mortality, and increasing the resources that
families and societies spend on the other, well planned children. In
a country with one of the highest levels of maternal mortality in
the world [1,30], contraception could have a substantial impact on
induced abortion-related morbidity and mortality in this setting of
legal and religious proscriptions. The NCP would reduce the
estimated 297,000 induced abortions performed annually in
Uganda by almost 50,000 [21], a significant contribution given
that post-abortion care, which is not illegal, is severely inadequate.
The finding that the NCP is highly cost-effective is consistent
with a previous study conducted in Uganda, which found that
satisfying all the unmet need for modern methods of contraception
would reduce maternal mortality by 40% and unplanned births
and induced abortions by 84–85% while saving $3 for every dollar
invested in reducing this unmet need [2]. The present study had
the added advantage of making a formal value assessment
including the performance of an incremental analysis that allows
for comparison with other healthcare interventions, incorporating
parameter uncertainty in the modeling framework, and modeling
the entire reproductive and life experience of women. And because
the model was primarily based on demographic and health survey
data, it can be replicated in other low-income countries with
similar surveys.
In dominating the CCP, the NCP out-competes a number of
health interventions that have been evaluated for cost-effectiveness
in Uganda such as facility-based care for HIV ($1,396 per quality-
adjusted life-year(QALY)) [13], group psychotherapy with rein-
forcement for depression ($1,150 per QALY) [31], home-based
antiretroviral therapy compared to using septrin alone ($597 per
DALY) [32], measles eradication ($284/DALY) [14], vitamin A
Table 5. Results of the baseline analysis showing the mean
costs (per woman), incremental costs, DALE, incremental
DALE and ICERs comparing NCP to the CCP.
CCP NCP
Societal MoH Societal MoH
Total cost ($) 1,987.29 684.81 1,949.40 636.03
Total incremental cost ($) 238.89 248.78
DALE (Years) 27.01 27.01 27.38 27.38
Incremental DALE (Years) 0.37 0.37
ICER ($/DALY) Dominant Dominant
Program cost 458.49 104.85 682.47 155.58
Incremental program cost 224.98 51.73
Medical cost 1,529.80 581.97 1,267.94 481.46
Averted medical costs 262.86 100.51
Net costs* 421.61 55.07
DALE – Disability-Adjusted Life Expectancy; DALY – Disability-Adjusted Life-
Year; MoH – Ministry of Health; CCP – Current Contraceptive Program; NCP –
New Contraceptive Program.
*Program costs minus averted medical costs.
doi:10.1371/journal.pone.0030735.t005
Table 6. Mean incremental costs (per woman) and health
outcomes comparing the new contraceptive program to the
current contraceptive program in Uganda*.
Outcome (mean) Value
Incremental societal cost ($) 237.9
Incremental MoH cost ($) 248.8
Incremental life expectancy (LYs) 0.09
Reduction in pregnancies 1.60
Reduction in fertility 1.13
Reduction in ectopic pregnancies 0.02
Reduction in miscarriages 0.07
Reduction in abortions 0.29
Reduction in still births 0.02
Reduction in noenatal deaths 0.03
Reduction in infant deaths 0.09
Reduction in child deaths 0.16
LYs – Life Years; ICER – Incremental Cost-Effectiveness Ratio.
*The NCP results in lower costs and improved outcomes i.e. dominates the CCP
in the incremental analysis.
doi:10.1371/journal.pone.0030735.t006
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and traffic enforcement ($27 per life-year saved) [34]. Additionally,
universal access to contraception would be comparatively
affordable; it is projected to cost $72 million [2] compared to
say, provision of facility-based care for HIV which would cost $461
million [13]. While cost-effectiveness and affordability are not the
only considerations for the allocation of the scarce healthcare
resources in a low-income country like Uganda, their combination
is quite compelling and might lead to the most efficient use of a
severely limited budget.
The trajectory of socioeconomic development is uncertain and
it is unclear what the impact of universal contraceptive access
would be on fertility intentions, ideal family size and preference for
different methods of family planning. Empirical inquiry into these
issues may be an area of potential future research to enable the
setting of ongoing policy in response to the dynamic nature of the
Figure 2. Tornado diagrams of univariate sensitivity analysis from the societal perspective. The diagram shows, for a comparison
between the new contraceptive program and the current contraceptive program, the impact of uncertainty surrounding different variables on
incremental cost (a) and incremental disability-adjusted life years (b). The most influential variables are shown.
doi:10.1371/journal.pone.0030735.g002
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of potential future research might be the improvement and
adaptation of our modeling framework for use in other countries
or settings as a tool to estimate the potential impact of
contraceptive programs and to help in the allocation of scarce
healthcare resources.
One limitation of the study was that it did not estimate the
potential change in fertility preference over time and assumed
constant fertility intentions. Future analyses might incorporate
changing fertility intentions which are likely to follow the
trajectory of socioeconomic development. Another limitation is
that we did not account for a change in the use distribution of
modern contraception for a new contraceptive program or over
the time horizon of the analysis. Future analyses might also
incorporate the likely changes in contraceptive use mix in light of
the on-going development of newer, more efficacious contracep-
tives with fewer adverse events.
Our study was also limited because we did not measure fully the
benefits of contraception. The main reason for contraception is
not to improve health but to limit or regulate fertility. This has
both direct health benefits and wider (indirect) health and
economic benefits to society and individuals including better
Figure 3. Incremental cost-effectiveness scatter plot obtained from probabilistic sensitivity analysis. The figure shows the distribution
of cost-effectiveness pairs on the cost-effectiveness plane.
doi:10.1371/journal.pone.0030735.g003
Figure 4. Cost-effectiveness acceptability curves obtained from probabilistic sensitivity analysis. The curves show, for 10,000 simulated
samples, the probability that the new contraceptive program is cost-effective compared to the current contraceptive program at varying thresholds
of cost-effectiveness (willingness to pay to avert an additional disability-adjusted life year).
doi:10.1371/journal.pone.0030735.g004
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prevention of maternal to child transmission of HIV, and
productivity and labor force benefits accruing to individuals and
society through improved maternal well-being. This study looked
at the direct health benefits to mothers and direct maternal health
costs only and likely underestimates the potential cost-effectiveness
of increasing contraceptive coverage. Future studies might explore
the potential economic impact of a wider array of benefits,
particularly impacts on child health.
Insummary,universalaccesstomoderncontraceptionappearsto
be highly cost-effective and would contribute directly to achieving
MDGs4(reducechildmortality)and5(improvematernalhealth).It
would also contribute indirectly to MDG 1 (eradicate extreme
hunger and poverty), MDG 2 (achieve universal primary educa-
tion), and MDG 3 (promote gender equality and empower women).
Therefore, policy makers in the national ministry of health and
other stakeholders and development partners should consider
urgent, concrete steps to increase access to modern contraceptives
to women in Uganda who need them.
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